Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lipopeptide AB
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Diabetic Foot|Inflammation|Melanoma|Leg Ulcer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2300067840 | N/A |
Recruiting |
COVID-19 |
2026-12-31 |
|
| ChiCTR2200063622 | N/A |
Recruiting |
Pneumonia|Coronavirus Infections |
2022-09-30 |
|
| 5P50CA093459-08 | P2 |
Completed |
Melanoma |
2020-11-24 |
|
| HEAL LL-37 | P2 |
Completed |
Leg Ulcer |
2020-07-13 |